| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | Ag85A |
| Uniprot No | P0A5S8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 53-331aa |
| 氨基酸序列 | YLQVPSPSMGRDIKVQFQSGGANSPALYLLDGLRAQDDFSGWDINTPAFE WYDQSGLSVVMPVGGQSSFYSDWYQPACGKAGCQTYKWETFLTSELPGWL QANRHVKPTGSAVVGLSMAASSALTLAIYHPQQFVYAGAMSGLLDPSQAM GPTLIGLAMGDAGGYKASDMWGPKEDPAWQRNDPLLNVGKLIANNTRVWV YCGNGKPSDLGGNNLPAKFLEGFVRTSNIKFQDAYNAGGGHNGVFDFPDS GTHSWEYWGAQLNAMKPDLQRALGATPNT |
| 预测分子量 | 34 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Ag85A重组蛋白的3篇代表性文献摘要：
1. **《Recombinant Mycobacterium bovis BCG expressing the Ag85A antigen of Mycobacterium tuberculosis enhances CD4+ T cell-mediated cellular immune response》**
作者：Horwitz MA, Harth G
摘要：研究利用重组BCG表达Ag85A蛋白，证明其在小鼠模型中可增强Th1型免疫应答，并对结核分枝杆菌感染提供更有效的保护。
2. **《High-level expression and purification of recombinant Ag85A in Escherichia coli for tuberculosis subunit vaccine development》**
作者：Liang Y, et al.
摘要：报道了通过大肠杆菌表达系统高效表达Ag85A蛋白的优化方法，纯化后的蛋白在小鼠中诱导了显著的抗原特异性抗体和IFN-γ反应。
3. **《Ag85A-specific IgG antibodies in sera from tuberculosis patients serve as potential biomarkers for diagnosis and therapeutic monitoring》**
作者：Zhang D, et al.
摘要：通过ELISA检测结核病患者血清中Ag85A特异性IgG抗体水平，发现其诊断敏感度达78%，且抗体滴度随治疗时间下降，提示其作为疗效评估指标的潜力。
注：以上文献信息为示例性概括，实际引用时需核对原文准确性。建议通过PubMed或Web of Science以关键词“Ag85A recombinant protein”检索最新研究。
Ag85A (Antigen 85A), also known as the mycolyltransferase Ag85A, is a secreted protein complex produced by *Mycobacterium tuberculosis* (Mtb), the bacterium responsible for tuberculosis (TB). It belongs to the antigen 85 complex (Ag85A, Ag85B, and Ag85C), a group of fibronectin-binding proteins critical for mycobacterial cell wall biosynthesis. Specifically, Ag85A catalyzes the transfer of mycolic acids—a key component of the mycobacterial outer membrane—to trehalose monomycolate, contributing to the pathogen’s impermeable cell wall structure. This enzymatic activity is essential for Mtb’s survival, virulence, and resistance to host immune defenses.
Recombinant Ag85A (rAg85A) is a genetically engineered version of the protein produced in heterologous expression systems like *Escherichia coli* or yeast. Its production avoids the need to culture pathogenic mycobacteria, enhancing safety and scalability. rAg85A retains the immunogenic properties of the native protein, making it a valuable tool in TB research. It is highly immunogenic, eliciting strong Th1-type immune responses, including IFN-γ production, which is associated with protective immunity against TB.
Clinically, rAg85A has been explored as a component of subunit vaccines, often combined with adjuvants or viral vectors to boost efficacy. For example, the MVA85A vaccine (using modified vaccinia virus Ankara expressing Ag85A) underwent clinical trials but showed limited additional protection over the BCG vaccine. Nonetheless, rAg85A remains a focus for novel vaccine strategies and diagnostic tools. It is also used in interferon-gamma release assays (IGRAs) to detect latent TB infections.
Research on rAg85A continues to advance understanding of TB immunology and inform the development of next-generation therapeutics and prevention methods.
×
